ERBB2 and neoplasm: In conclusion, the data presented here indicate that the maximum benefit of neoadjuvant anti-HER2 therapy is observed in the subgroup of patients with tumours that are HER2 IHC 3+, histological grade 3 or IHC 2+/HER2 amplification co-existing with ER-negativity.